The global pentavalent antimonials market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Pentavalent antimonials are a class of compounds used for the treatment of leishmaniasis. Antimonials have largely been used for the treatment of cutaneous and mucocutaneous leishmaniasis. These are widely available for use as an aqueous solution for intravenous or intramuscular use. Pentavalent antimonials are available as Sodium stibogluconate and meglumine antimoniate. Advances in existing anti-leishmanial drugs which further result in effective and safer formulations, have been witnessed as the latest market trend which is primarily driving the market growth. For instance, as per the data of the Drugs for Neglected Diseases initiative (DNDi), 2 new chemical entities labelled as DNDI-6148 and DNDI-0690 were introduced into the preclinical development stage for the treatment of visceral and cutaneous leishmaniasis in 2016. 

Immunomodulator- CpG-D35, is also in a pre-clinical development stage, which is proposed to be used as an adjunct apart from the main drug therapy to treat cutaneous leishmaniasis. Such developments and advancements are anticipated to augment the global market growth. Additionally,  several initiatives and government efforts have been witnessed to increase visceral leishmaniasis surveillance, diagnosis, vector control, as well as its treatment, which ultimately, is projected to positively impact the market growth. For instance, the World Health Organization (WHO) had launched an action plan for reducing the impact of Neglected Tropical Diseases (NTDs), including visceral leishmaniasis in 2012. 

Some key players operating in the market include Sanofi S.A. and GlaxoSmithKline plc, among others. The market players are focusing on strengthening their position in the market by adopting various strategies such as mergers and acquisitions, partnerships, collaborations, new product launches and development in the existing product portfolio, and so on. For instance, in 2016, the WHO and Gilead Sciences, Inc. signed an agreement to donate 380,400 vials of AmBisome (liposomal amphotericin B), extending their previous agreement from 2016 to 2021. This five-year collaboration aided by the funding of $20 million by Gilead Sciences, Inc. is aimed to provide access to diagnosis and treatment to the populations affected by visceral leishmaniasis in key endemic countries, majorly India, Ethiopia, South Sudan, Nepal, Bangladesh, and Sudan.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape:  Sanofi S.A. and GlaxoSmithKline plc, among others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Pentavalent Antimonials Market Report by Segment

By Type

• Sodium Stibogluconate

• Meglumine Antimoniate

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Online Pharmacies

Global Pentavalent Antimonials Market by Region